Notice: Internet Explorer 11 users may encounter issues loading pages throughout the website. Please turn on IE-11’s compatibility mode while we work to resolve the issue.

>

MEETINGS / EVENTS

RSS

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit

>

FDA MEDWATCH ALERTS

November 21, 2014

FDA MedWatch - Respironics California, Esprit V1000 and V200 Ventilators: Class I Recall - Power Failure May Occur

Summary:

FDA MedWatch Respironics California Esprit V1000 and V200 Ventilators Class I Recall

November 07, 2014

FDA MedWatch - Nellcor Puritan Bennett, 980 Ventilator System: Class I Recall - Software Issue May Stop Ventilator

Summary:

FDA MedWatch Nellcor Puritan Bennett 980 Ventilator System Class I Recall

October 25, 2014

FDA MedWatch - Intravia Containers by Baxter: Recall - Particulate Matter

Summary:

FDA MedWatch Intravia Containers by Baxter Recall

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

Positive Update on Succinylcholine Drug Shortage

Thursday, July 21, 2011

On July 19, the Food and Drug Administration Drug Shortage Division reported that there are now two companies, Hospira and Sandoz, producing succinylcholine injections. The two manufacturers are now able to provide enough products to meet the market demands.  This is a positive development for patients and physicians across the country. In an April 2011 ASA survey on drug shortages, 47.6 percent of respondents reported currently experiencing a shortage of succinylcholine.

When ASA members first reported the shortage of succinylcholine, the ASA reached out to the FDA. Since that time, ASA has worked closely with the FDA on potential remedies for the shortage. ASA commends the great work performed by the FDA staff in helping to alleviate this shortage. While this is a positive development, ASA is fully aware that it will take time for the product to move through the market to become available to providers for use on patients.   

To read more about all of the work the ASA is doing on drug shortages, click here.

 

 

 

« Back to Washington Alerts